– USA, IL – AbbVie (NYSE: ABBV) today announced the selection of current independent director Roxanne Austin as lead independent director, effective July 1, 2024, succeeding Glenn Tilton who remains on the Board as an independent director.
“One of AbbVie’s greatest strengths is an experienced, diverse and highly independent Board of Directors committed to the highest standards of corporate governance,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “The appointment of Roxanne as lead independent director reflects a thorough and deliberate process by the independent directors of the Board, who strongly believe that her experience and leadership ability make her highly qualified to lead the AbbVie Board. Roxanne has provided keen insights and guidance as an independent director since joining the Board in 2013. I’m delighted that she will bring her expertise to us in this role, especially as we make the important transition in executive leadership when Rob Michael assumes the role of AbbVie’s CEO on July 1.”
About Roxanne Austin
Roxanne Austin is president of Austin Investment Advisors, a private investment and consulting firm. She chaired the U.S. Mid-market Investment Advisory Committee of EQT Partners from 2017 to 2023. Previously, Ms. Austin also served as the president and CEO of Move Networks, Inc., a provider of Internet television services. Roxanne Austin served as president and CEO of DIRECTV, Inc. She also served as EVP and CFO of Hughes Electronics Corporation and as a partner of Deloitte & Touche LLP. Roxanne Austin is also a director of Crowdstrike, Inc., Freshworks, Inc., and Verizon Communications Inc. Ms. Austin previously served as a director of Abbott Laboratories from 2000 to 2022, Teledyne Technologies, Inc. from 2006 to 2021, Target Corporation from 2002 to 2020, and Telefonaktiebolaget LM Ericsson from 2008 to 2016.
“I am honored to have received the support of AbbVie’s Board in this important role, and I am excited to partner with the Board and management team as we embark on this important next phase in AbbVie’s growth,” said Roxanne Austin. “I would like to thank Glenn for his invaluable guidance as an independent director for many years. His leadership has been marked by integrity, intelligence and determination, and AbbVie will benefit tremendously by his continued service on the Board.”
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
For more: https://www.abbvie.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.